[go: up one dir, main page]

WO2015076244A1 - Agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'aphanothece sacrum - Google Patents

Agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'aphanothece sacrum Download PDF

Info

Publication number
WO2015076244A1
WO2015076244A1 PCT/JP2014/080454 JP2014080454W WO2015076244A1 WO 2015076244 A1 WO2015076244 A1 WO 2015076244A1 JP 2014080454 W JP2014080454 W JP 2014080454W WO 2015076244 A1 WO2015076244 A1 WO 2015076244A1
Authority
WO
WIPO (PCT)
Prior art keywords
disaccharide structure
molecular weight
pentose
polysaccharide
deoxyhexose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/080454
Other languages
English (en)
Japanese (ja)
Inventor
有馬　英俊
敬一 本山
大志 東
河添　宏
慎一郎 金子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GREEN SCIENCE MATERIAL Inc
Kumamoto University NUC
Resonac Corp
Original Assignee
GREEN SCIENCE MATERIAL Inc
Hitachi Chemical Co Ltd
Kumamoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GREEN SCIENCE MATERIAL Inc, Hitachi Chemical Co Ltd, Kumamoto University NUC filed Critical GREEN SCIENCE MATERIAL Inc
Priority to JP2015549146A priority Critical patent/JPWO2015076244A1/ja
Publication of WO2015076244A1 publication Critical patent/WO2015076244A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to an anti-inflammatory agent containing a low-molecular-weight polysaccharide derived from suizendinori.
  • Inflammation is a reaction that occurs when a living body is damaged, and is a local protective reaction that is caused by the immune system against cell and tissue damage.
  • the signs of inflammation can include five major signs of redness, swelling, heat, pain, and dysfunction.
  • Anti-inflammatory drugs that suppress inflammation are mainly classified into two types: steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs.
  • steroidal anti-inflammatory agents include corticosteroids such as hydrocortisone, prednisolone, and triamcinolone, and have an inhibitory effect on the synthesis of prostaglandins.
  • non-steroidal anti-inflammatory agents include salicylic acid, indomethacin, ibuprofen, etc., and exhibit high anti-inflammatory activity by inhibiting the synthesis of prostaglandins.
  • side effects such as gastrointestinal disorders and renal dysfunction are concerned.
  • an attempt to search for a substance having an anti-inflammatory action from a natural product and use it as a new anti-inflammatory agent is also widely performed.
  • it is obtained from, for example, an anti-inflammatory agent containing, as an active ingredient, an acidic xylo-oligosaccharide obtained from wood or the like
  • Patent Document 1 Japanese Patent Publication No. 2003-221339
  • An anti-inflammatory agent containing an anti-inflammatory substance as an active ingredient Patent Document 2: Japanese Patent Publication No.
  • Patent Document 4 Japanese Patent Application Laid-Open No. 2008-120716.
  • glucosaminoglycans such as hyaluronic acid, dermatan sulfate, and chondroitin sulfate have anti-inflammatory effects, and some are marketed as pharmaceuticals.
  • hyaluronic acid has been reported to suggest the possibility of promoting canceration, and there are concerns about safety.
  • Sakuran is a novel ultra-high molecular weight polysaccharide with a weight average molecular weight of about 20 million, which is extracted from suizendinori, an edible cyanobacteria unique to Japan.
  • Sakuran (Suizendinori polysaccharide) is an ampholyte having many sulfate groups, carboxylic acid groups, and amino groups.
  • the molecular structure of sakuran changes depending on the concentration in the solution, and it exists in the form of nanometer-sized particles in the low concentration region. Form.
  • the weight average molecular weight of cherry is as high as about 20 million, and it becomes highly viscous at high concentration, so that it is expected that the permeability to the skin will decrease.
  • the present inventors have confirmed that the anti-inflammatory action of cherry is attenuated at a high concentration, and there is a problem in using cherry itself as an anti-inflammatory agent.
  • An object of the present invention is to provide a highly safe anti-inflammatory agent that can suppress inflammation.
  • sakuran exhibits an anti-inflammatory action in an inflammation model, and is further sometimes referred to as a low-molecular-weight polysaccharide derived from Suizendinori derived from sakuran having a specific weight average molecular weight (hereinafter simply referred to as a low-molecular-weight polysaccharide). ) Has an excellent anti-inflammatory action, and the present invention has been completed.
  • the present invention includes the following.
  • the weight average molecular weight is about 2,000 or more (preferably about 5,000 or more, more preferably about 10,000 or more) and about 3 million or less (preferably about 2 million or less, more preferably about 1 million or less).
  • An anti-inflammatory agent comprising a low molecular weight polysaccharide derived from a suizendinori or a pharmacologically acceptable salt derivative thereof.
  • the low-molecular-weight polysaccharide derived from Suizendinori contains sulfated muramic acid as a sugar structure, and at least the following formula:
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • the anti-inflammatory agent according to (1) or (2) above which is a sugar derivative containing any of the above.
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • the anti-inflammatory agent according to (1) or (2) above which is a mixture of sugar derivatives containing all of the above.
  • the weight average molecular weight is about 2,000 or more (preferably about 5,000 or more, more preferably about 10,000 or more) and about 3 million or less (preferably about 2 million or less, more preferably about 1 million or less).
  • a therapeutic or prophylactic agent for atopic dermatitis comprising a certain suizendinori-derived polysaccharide low molecular weight product or a pharmacologically acceptable salt derivative thereof as an active ingredient.
  • a weight-average molecular weight of the low molecular weight product of the suizendinori-derived polysaccharide is about 10,000 or more and about 1 million or less (preferably about 30,000 or more and about 1 million or less).
  • a therapeutic or prophylactic agent for dermatitis. contains sulfated muramic acid as a sugar structure, and at least the following formula:
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • the therapeutic or preventive agent for atopic dermatitis according to (7) or (8) above, which is a sugar derivative containing any of the above.
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • the therapeutic or preventive agent for atopic dermatitis according to (7) or (8) above, which is a mixture of sugar derivatives containing all of the
  • an anti-inflammatory agent that can suppress inflammation and has high safety is provided.
  • the low molecular weight polysaccharide-derived polysaccharide having a specific average molecular weight used in the present invention can be obtained from cherry, which is a sulfated polysaccharide having a weight average molecular weight of about 20 million derived from Aphanothece sacrum.
  • Suizenjinori (Aphanothece ⁇ sacrum) is a freshwater cyanobacteria that forms a colony in the state that a large number of single cells (size: 3.5-4.0 ⁇ ⁇ 6-7 ⁇ ) are buried in agar. Growth has been confirmed only in Kumamoto Prefecture and Fukuoka Prefecture in the Kyushu region.
  • Sakuran has a repeating structure of a sugar chain unit in which a sugar structure having a hexose structure and a sugar structure having a pentose structure are linked in a linear or branched manner by ⁇ -glycoside bonds or ⁇ -glycoside bonds, and
  • the chain unit contains sulfated muramic acid as a sugar structure, and in the sugar chain unit, 2.7 or more hydroxyl groups per 100 hydroxyl groups are sulfated, or the sulfur element is 1.5% in all elements. It is characterized by containing a sugar derivative occupying at least% by weight.
  • Sakura has a weight average molecular weight of about 20 million, contains sulfated muramic acid as a sugar structure, and has at least the following formula:
  • a trisaccharide structure having the sequence shown in 1) and the sequences listed in the following 1) to 6): 1) Disaccharide structure of hexose and pentose which is xylose or arabinose, 2) Disaccharide structure of hexose and deoxyhexose which is fucose or rhamnose, 3) Disaccharide structure of pentose and pentose, 4) Disaccharide structure of pentose and deoxyhexose, 5) Disaccharide structure of hexosamine and hexosamine, 6) Disaccharide structure of uronic acid which is glucuronic acid or galacturonic acid and deoxyhexose, It is a sugar derivative containing all of the disaccharide structure having
  • a cherry tree can be extracted from a lily of the valley by adding it to a 0.1N NaOH aqueous solution at 80 ° C. and stirring for several hours.
  • cherry blossoms can be extracted from the water lily by heating an aqueous dispersion of water lily in an autoclave at 135 ° C. for 30 minutes.
  • the extracted cherry may be purified by centrifugation, filtration, alcohol washing or the like.
  • cherry is an acidic polysaccharide and can be extracted from scorpionary using an alkaline solution.
  • the cherry tree extracted from a suizenjinori can be obtained from Daito Kasei Co., Ltd., for example.
  • Examples of the method for reducing the molecular weight of the cherry include acid hydrolysis by heat treatment under acidic conditions, but are not limited thereto.
  • the low molecular weight product of cherry can be used by any method, for example, but not limited to, fractionating a specific molecular weight using gel filtration chromatography.
  • the polysaccharide low molecular weight product contained in the anti-inflammatory agent or the atopic dermatitis treatment / prevention agent of the present invention is a polysaccharide that can be obtained from the above cherry. Is the body.
  • the polysaccharide low-molecular-weight product used in the present invention may be composed of a uniform polysaccharide or a mixture of various polysaccharides. However, since it is usually prepared from natural cherry, It consists of a mixture of polysaccharides.
  • the polysaccharide-reduced product used in the present invention can be obtained by degrading natural cherry, but the method of preparation is not limited thereto.
  • the polysaccharide-reduced product of the polysaccharide of the present invention is a polysaccharide that can be obtained from the above cherry, and has a weight average molecular weight of about 3 million or less, preferably about 2 million or less, more preferably about 1 million or less, Further, the lower limit of the weight average molecular weight is about 2,000 or more, preferably about 5,000 or more, more preferably about 10,000 or more polysaccharides containing sulfated saccharides, or polysaccharides having an equivalent structure thereof, These are various derivatives (for example, salt derivatives of polysaccharides) obtained from polysaccharides by conventional methods.
  • the weight average molecular weight here can be measured by a conventional method, and can be measured, for example, using gel filtration chromatography.
  • the weight average molecular weight of the low molecular weight polysaccharide used in the present invention is, for example, about 2,000 or more and about 3 million or less.
  • a method for measuring an arbitrary weight molecular weight of the low molecular weight polysaccharide used for example, gel filtration chromatography). (Polygraph)), a mixture of polysaccharides derived from Sakuran whose (weight) average molecular weight determined from the distribution is between about 2,000 and about 3 million may be used. Or a mixture thereof).
  • the low molecular weight cherry used in the present invention is preferably a mixture of polysaccharides showing one peak when the molecular weight is measured by gel filtration chromatography, but may be a mixture of polysaccharides showing a plurality of peaks. Good.
  • the polysaccharide low molecular weight product used in the present invention is not limited as long as the polysaccharide low molecular weight product used or a mixture thereof falls within the range of the weight average molecular weight defined in the present invention. More preferably a mixture showing a sharper peak.
  • “Sacran (molecular weight 1,500,000)”, “Sacran (molecular weight 940,000)”, “Sacran (molecular weight 45,000)”, and “Sacran (molecular weight 900)” are decomposed or processed. And a mixture of polysaccharides each having a weight average molecular weight of about 1.5 million, about 940,000, about 45,000, or about 900, respectively. means.
  • the polysaccharide low molecular weight product of the present invention can be expressed not only by the weight average molecular weight but also by the average number of sugars (in such a case, the weight average molecular weight of the monosaccharide can be estimated to be about 180).
  • the polysaccharide low molecular weight product of the present invention is a polysaccharide that can be obtained from the above sakuran, and the upper limit of the average number of sugars is about 10 4 or less, preferably about 10 3 or less, and the average number of sugars
  • the lower limit of the polysaccharide is about 10 or more, preferably about 20 or more, more preferably about 50 or more, more preferably about 10 2 or more of a polysaccharide containing a sulfated sugar, or a polysaccharide having an equivalent structure,
  • the average number of sugars referred to here is a value obtained by converting the size of a sugar derivative into the number of sugars constituting the sugar derivative.
  • a cherry derivative composed of a sugar derivative having an average sugar number of 10 4 is an aggregate of sugar derivatives having a sugar number between about 10 3 and about 10 5 (a sugar number on the order of 10 4 (ie, around the derivatives of sugars several tens of thousand-hundred thousand) means confusion induced composed distributed), and confusion induced composed average number sugar from 10 3 sugar derivative is from about 10 2 to about 10
  • Sakura derivatives composed of 10 2 sugar derivatives are aggregates of sugar derivatives having a sugar number between about 10 1 and about 10 3 (number of sugars on the order of 10 2 (that is, hundreds to thousands of sugars). ), Which is distributed around the derivative).
  • “Sacran (molecular weight: 1,500,000)”, “Sacran (molecular weight: 940,000)”, “Sacran (molecular weight: 45,000)”, and “Sacran (molecular weight: 900)” indicated by the weight average molecular weight are indicated by the average number of sugars. These can be expressed as “Sacran (10 4 )”, “Sakuran (10 3 )”, “Sakuran (10 2 )”, and “Sakuran (4)”, respectively.
  • the above polysaccharide having an equivalent sugar structure includes, for example, sulfated muramic acid as the sugar structure, and at least the following formula:
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • the sugar structure contains sulfated muramic acid, and at least the following formula:
  • R and R ′ represent a saccharide, and any —OH in the formula may be replaced by —OSO 3 or —OCH 3
  • a suizendinori-derived polysaccharide low molecular weight product having a desired weight average molecular weight can be obtained from Sakuran by a combination of known methods. For example, it can be obtained by heat treatment under acidic conditions and acid hydrolysis.
  • a sugar chain can be randomly cleaved using a known sugar chain cleavage method, for example, an enzyme, and a mixture of sugar derivatives having a desired weight average molecular weight can be isolated based on the molecular weight.
  • Examples of enzymes that can cleave the sugar chain of cherry include ⁇ -galactosidase, hexosaminidase A, hexosaminidase B, ⁇ -galactosidase A, ⁇ -glucosidase, ⁇ -L-iduronidase, N-acetyl- ⁇ .
  • the end of the cleaved sugar chain can be arbitrarily modified.
  • functional groups that can be used for modification include, but are not limited to, a carboxy group, an amino group, and a sulfate group.
  • Derivatives in which these cleaved sugar chains are modified or substituted are also included in the polysaccharide low molecular weight product of the present invention.
  • a hydroxyl group or a hydrogen group of a sugar constituting sakuran, or a carboxy group an amino group or other group bonded to the sugar is substituted or It is also possible to modify these derivatives, and these modified or substituted derivatives are also included in the polysaccharide low molecular weight product of the present invention.
  • the low molecular weight polysaccharide of the present invention can also be used in the form of a pharmacologically acceptable salt.
  • the pharmacologically acceptable salt is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include inorganic salts such as hydrochloride and sulfate, and organic acid salts such as citric acid. Can do.
  • the content of the low-molecular-weight polysaccharide in the pharmaceutical composition of the present invention can be appropriately selected according to the use and purpose.
  • the content of the polysaccharide can be 0.0001 to It is 20% by weight, preferably 0.001 to 10% by weight, and more preferably 0.01 to 5% by weight.
  • the pharmaceutical composition of the present invention can be used in any form and is not limited thereto, and examples thereof include oral preparations, injection preparations, external preparations for skin, topical preparations, eye drops and the like.
  • the polysaccharide low-molecular-weight product of the present invention has a moisturizing action in addition to an anti-inflammatory action, it is preferably used in an embodiment as a topical administration agent or an injection or an eye drop for external preparations for skin and arthritis.
  • the dosage form When used as an external preparation for skin, the dosage form is arbitrary, and for example, it can be used in various forms such as liquids, ointments, patches, aerosols, haps, tapes, and powders.
  • the dosage form When used as an oral preparation, the dosage form is arbitrary, and can be used in various forms such as tablets, capsules, granules, powders and the like.
  • the pharmaceutical composition of the present invention can contain components appropriately selected according to the purpose, in addition to the polysaccharide low molecular weight product of the present invention.
  • auxiliary ingredients for formulation include bases, stabilizers, preservatives, preservatives, emulsifiers, suspending agents, solubilizers, solubilizers, lubricants, flavoring agents, colorants, fragrances , Soothing agents, excipients, binders, thickeners, buffers, and the like.
  • the auxiliary components may be appropriately selected and used.
  • assistant component should just be suitably selected according to a dosage form etc. in the range accept
  • excipients when used as an external preparation for skin, for example, excipients, binders, flavoring agents, emulsifiers, surfactants, solubilizing agents, suspending agents , And can be formulated by appropriately combining isotonic agents, preservatives, antioxidants, stabilizers or absorption promoters.
  • an emulsifier, a surfactant, a solubilizer, a suspending agent, a tonicity agent, a buffer, an antiseptic, an antioxidant, a stabilizer, or an absorption enhancer is appropriately used. It can be formulated in combination.
  • the pharmaceutical composition containing the polysaccharide low molecular weight product of the present invention can be widely used for diseases accompanied by inflammation, for example, infection, rheumatoid arthritis, collagen disease, gout, allergic disease, atopic dermatitis, inflammatory bowel
  • diseases accompanied by inflammation for example, infection, rheumatoid arthritis, collagen disease, gout, allergic disease, atopic dermatitis, inflammatory bowel
  • the polysaccharide low molecular weight product of the present invention is an anionic polysaccharide derived from a natural product, it is excellent in safety.
  • the polysaccharide low-molecular-weight product of the present invention is relatively stable against heat, can be sterilized by autoclave, is easy to handle, and has an advantage of being suitable for pharmaceutical use.
  • Example 1 Preparation of Sakura Water Solution and Inflammation Model (1) Preparation of Sakura Water Solution
  • a low molecular weight polysaccharide derived from Suizendinori a low molecular weight polysaccharide derived from sakuran having a weight average molecular weight of about 800 to 1000 (sakuran (molecular weight 900)), a low molecular weight polysaccharide having a weight average molecular weight of about 45,000 (Sakuran (molecular weight 45,000)), and a low molecular weight polysaccharide having a weight average molecular weight of about 940,000 (Sakuran (molecular weight 940,000)).
  • a low molecular weight polysaccharide having a weight average molecular weight of about 1,500,000 (Sakuran (molecular weight 1,500,000)) (all manufactured by Hitachi Chemical Co., Ltd.).
  • the molecular weight of each low-molecular-weight polysaccharide is measured by connecting a GPC column (GL-W560, Hitachi High-Technologies Corporation) to an HPLC system equipped with a differential refractometer (Shimadzu Corporation, RID-10A) as a detector.
  • the carrageenin-induced rat footpad edema model was prepared by injecting 100 ⁇ L of carrageenin ( ⁇ -carrageenin (SIGMA, Lot No.0001408463) 1% aqueous solution) into the rat footpad in accordance with a conventional method. Created with edema.
  • ⁇ -carrageenin SIGMA, Lot No.0001408463
  • Example 2 Anti-inflammatory effect by repeated administration of low molecular weight polysaccharide-derived polysaccharides from Suizendinori Immediately after carrageenin administration to the footpad of rats, 100 ⁇ L of an aqueous solution containing various low-molecular-weight polysaccharides derived from Suizendinori was applied once every hour. did. Application was repeated 6 times. The concentration of the polysaccharide low molecular weight aqueous solution used was 0.0005% (w / v) for cherry (molecular weight 1,500,000), cherry (molecular weight 940,000), and cherry (molecular weight 45,000), and cherry (molecular weight). 900) was 0.02% (w / v).
  • the low molecular weight polysaccharide derived from Suizen Ginori has an anti-inflammatory effect equivalent to or higher than that of Sakuran in an amount of 1/100, and strong anti-inflammatory even at a low concentration of 0.0005% (w / v). The effect was shown.
  • Example 3 Anti-inflammatory action by pretreatment of low molecular weight polysaccharide-derived polysaccharide derived from suizendinori
  • low molecular weight polysaccharide-derived polysaccharide derived from suizendinori was applied to the rat footpad before inducing inflammation by carrageenan The anti-inflammatory effect was confirmed.
  • the polysaccharide low molecular weight product was applied 1 hour before carrageenan administration.
  • the concentration of the polysaccharide low molecular weight product aqueous solution used was 0.0005% (w / v) for cherry (molecular weight 1,500,000), cherry (molecular weight 940,000), and cherry (molecular weight 45,000).
  • Example 4 Concentration dependence of anti-inflammatory action of low molecular weight polysaccharide derived from Suizendinori
  • concentration of the polysaccharide low-molecular-weight aqueous solution used was 0.0005% (w / v), 0.005% (w / v), and 0.01% (w / v). .05% (w / v)) and physiological saline.
  • FIG. 3 shows the results of cherry (molecular weight 1,500,000)
  • FIG. 4 shows the results of cherry (molecular weight 940,000)
  • FIG. 5 shows the results of cherry (molecular weight 45,000). All of the low molecular weight cherries showed a concentration-dependent anti-inflammatory effect.
  • Comparative Example 1 Concentration dependence of anti-inflammatory action by cherry (natural cherry)
  • an aqueous solution containing various concentrations of cherry (natural cherry) immediately after administration of carrageenan to the rat footpad 100 ⁇ L was applied once every hour. Application was repeated 6 times.
  • the concentration of the sakura aqueous solution used was 0.01% (w / v), 0.05% (w / v), 0.1% (w / v), and 0.2% (w / v).
  • Saline was used as the subject.
  • the increase in paw volume was measured using a plethysmometer, and the rat footpad was protected with a lap after each measurement. The results are shown in FIG. In natural cherries, the anti-inflammatory effect was found to decrease with increasing concentration.
  • the low molecular weight product derived from Suizendinori has a strong and concentration-dependent anti-inflammatory effect compared to natural sakuran (non-decreased sakuran). It was found that it can be used as an inflammatory drug. Moreover, in the case of a polysaccharide low molecular weight product derived from Suizendinori, it is possible to set a wide range of administration concentrations, unlike a natural type cherry.
  • the low molecular weight polysaccharide-derived polysaccharide of the Suizendinori of the present invention is useful as an active ingredient of an anti-inflammatory agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　La présente invention concerne un agent anti-inflammatoire contenant un nouveau composant capable de réduire l'inflammation et présentant un degré élevé d'innocuité. La présente invention concerne un agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'Aphanothece sacrum, le polysaccharide étant dérivé de sacran extrait d'Aphanothece sacrum. Le polysaccharide faible poids moléculaire issu d'Aphanothece sacrum est un dérivé glucidique contenant un sucre sulfaté ayant un poids moléculaire moyen en poids inférieur ou égal à environ 3 000 000, le dérivé glucidique étant dérivé du sacran. La présente invention concerne une composition pharmaceutique, en particulier un anti-inflammatoire dermique, contenant un polysaccharide de faible poids moléculaire issu d'Aphanothece sacrum.
PCT/JP2014/080454 2013-11-19 2014-11-18 Agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'aphanothece sacrum Ceased WO2015076244A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015549146A JPWO2015076244A1 (ja) 2013-11-19 2014-11-18 スイゼンジノリ由来多糖体低分子化物を用いた抗炎症剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-238733 2013-11-19
JP2013238733 2013-11-19

Publications (1)

Publication Number Publication Date
WO2015076244A1 true WO2015076244A1 (fr) 2015-05-28

Family

ID=53179506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/080454 Ceased WO2015076244A1 (fr) 2013-11-19 2014-11-18 Agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'aphanothece sacrum

Country Status (3)

Country Link
JP (1) JPWO2015076244A1 (fr)
TW (1) TW201609112A (fr)
WO (1) WO2015076244A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017057032A1 (fr) * 2015-09-30 2017-04-06 稲葉　葉一 Préparation non stéroïdienne pour usage externe comprenant de l'ion argent et un polysaccharide d'aphanothece sacrum
JP2018199654A (ja) * 2017-05-29 2018-12-20 大東化成工業株式会社 有害物質除去方法
JP2020040900A (ja) * 2018-09-10 2020-03-19 国立大学法人 熊本大学 腎臓病の進行抑制剤、予防剤、および治療剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020142211A1 (fr) * 2019-01-02 2020-07-09 The Procter & Gamble Company Compositions de soin de la peau contenant un composé peptidique et un extrait d'exopolysaccharide d'aphanothece sacrum
CN113101299A (zh) * 2021-03-04 2021-07-13 圣珂兰投资有限公司 水前寺蓝藻多糖在制备治疗烫伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113435A1 (fr) * 2008-03-14 2009-09-17 Kaneko Tatsuo Préparation de dérivé de glucide
WO2011013496A1 (fr) * 2009-07-31 2011-02-03 国立大学法人北陸先端科学技術大学院大学 Procédé pour la préparation d'un polysaccharide issu d'aphanothece sacrum ayant une teneur réduite en métaux trivalents
JP2014205751A (ja) * 2013-04-11 2014-10-30 日立化成株式会社 スイゼンジノリ多糖体低分子化物及びスイゼンジノリ由来多糖類の低分子化方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113435A1 (fr) * 2008-03-14 2009-09-17 Kaneko Tatsuo Préparation de dérivé de glucide
WO2011013496A1 (fr) * 2009-07-31 2011-02-03 国立大学法人北陸先端科学技術大学院大学 Procédé pour la préparation d'un polysaccharide issu d'aphanothece sacrum ayant une teneur réduite en métaux trivalents
JP2014205751A (ja) * 2013-04-11 2014-10-30 日立化成株式会社 スイゼンジノリ多糖体低分子化物及びスイゼンジノリ由来多糖類の低分子化方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANN ALLERGY ASTHMA IMMUNOL, vol. 108, no. 2, 2012, pages 117 - 122 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017057032A1 (fr) * 2015-09-30 2017-04-06 稲葉　葉一 Préparation non stéroïdienne pour usage externe comprenant de l'ion argent et un polysaccharide d'aphanothece sacrum
JPWO2017057032A1 (ja) * 2015-09-30 2018-07-12 稲葉　葉一 銀イオン及びスイゼンジノリ多糖体配合非ステロイド外用剤
JP2018199654A (ja) * 2017-05-29 2018-12-20 大東化成工業株式会社 有害物質除去方法
JP2020040900A (ja) * 2018-09-10 2020-03-19 国立大学法人 熊本大学 腎臓病の進行抑制剤、予防剤、および治療剤
JP6996460B2 (ja) 2018-09-10 2022-01-17 国立大学法人 熊本大学 腎臓病の進行抑制剤、予防剤、および治療剤

Also Published As

Publication number Publication date
JPWO2015076244A1 (ja) 2017-03-16
TW201609112A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
WO2015076244A1 (fr) Agent anti-inflammatoire contenant un polysaccharide de faible poids moléculaire issu d'aphanothece sacrum
CN101534842B (zh) 用于治疗特应性皮炎的包含透明质酸和/或其盐的组合物
KR102360658B1 (ko) 항알레르기성 미용 조성물
JP2020500945A (ja) 硫酸化多糖を含む組成物
Codina et al. Efficacy of albendazole: β-cyclodextrin citrate in the parenteral stage of Trichinella spiralis infection
JP2011520850A5 (ja) エモリエント組成物
EP2854784B1 (fr) Méthode de traitement de maladies inflammatoires de la peau
Mythilypriya et al. Efficacy of Siddha formulation Kalpaamruthaa in ameliorating joint destruction in rheumatoid arthritis in rats
JP5622357B2 (ja) アレルギー性疾患の予防または治療薬
RU2450816C2 (ru) Композиции на основе солей гиалуроновой кислоты для лечения эпителиальных повреждений
EP2813215B1 (fr) Préparation de microsphères lipidiques de 2,2',6,6'-tétraisopropyl-4,4'-2-biphénol et leur procédé de préparation
HK1198632A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field
KR102838897B1 (ko) 글리시린을 포함하는 조성물 및 그의 미용적 용도 및 약제학적 용도
EP3551165B1 (fr) Compositions pharmaceutiques topiques ainsi que des dispositifs médicaux les comprenant pour le traitement de troubles cutanés
CN109562041A (zh) 具有牛磺酸的固体清洁组合物和其方法
JP2013010700A (ja) ヒアルロニダーゼ阻害剤
JP7594344B2 (ja) 外用組成物
JP6566322B2 (ja) 透明水性外用製剤
CA3154360C (fr) Polysaccharides pour la reduction des polypes nasaux
JP7638759B2 (ja) 医薬品または化粧品組成物
CN120112299A (zh) 用于治疗疼痛和其他医学病症的硫酸化糖胺聚糖及其衍生片段的储存稳定的制剂
JP6815782B2 (ja) α−ＳＭＡ産生抑制剤
JP2008156327A (ja) フルチカゾン含有医薬組成物
CN104173382A (zh) 林蛙提取混合液及其在治疗及预防脚气的药物中的用途
HK1261649B (zh) 抗皮肤过敏的化妆品组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14864854

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015549146

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14864854

Country of ref document: EP

Kind code of ref document: A1